U.S., March 18 -- ClinicalTrials.gov registry received information related to the study (NCT07476872) titled 'Gecacitinib in the Treatment of Steroid-Refractory/Dependent Chronic Graf Versus Host Disease (cGVHD).' on Feb. 26.
Brief Summary: This study aims to evaluate the safety and efficacy of Gecacitinib in patients with steroid-refractory/dependent active chronic graft versus host disease (cGVHD).
Study Start Date: March 16
Study Type: INTERVENTIONAL
Condition:
cGVHD
HSCT
Intervention:
DRUG: Gecacitinib
Phase Ib: Four dose cohorts of Gecacitinib are planned: 50 mg qd, 50 mg bid, 150 mg/day, and 100 mg bid. Dose escalation or de-escalation will follow the standard "3+3" design, starting at 50 mg BID. The dose may be escalated to 1...